ZLAB:NSD-Zai Lab Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 31.32

Change

0.00 (0.00)%

Market Cap

USD 3.39B

Volume

1.02M

Analyst Target

USD 98.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is based in Shanghai, China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing ZLAB

SBIO ALPS Medical Breakthrough.. 3.03 % 0.50 %

N/A

USD 0.08B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
CHB 0.00 % 1.12 %

N/A

N/A
HAO Haoxi Health Technology L.. 0.00 % 0.63 %

N/A

N/A
CHIH 0.00 % 0.00 %

N/A

N/A
EMSD:LSE SPDR MSCI Emerging Market.. 0.00 % 0.00 %

N/A

N/A
SPYX:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.00 %

N/A

USD 0.30B
EMSM:XETRA Invesco Markets plc - Inv.. 0.00 % 0.00 %

N/A

USD 0.36B
SPYX:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.59% 83% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.59% 83% B 86% B+
Trailing 12 Months  
Capital Gain 74.78% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.78% 91% A- 92% A
Trailing 5 Years  
Capital Gain -50.68% 63% D 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.68% 62% D 25% F
Average Annual (5 Year Horizon)  
Capital Gain -15.29% 31% F 18% F
Dividend Return -15.29% 31% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.34% 58% F 33% F
Risk Adjusted Return -28.14% 34% F 23% F
Market Capitalization 3.39B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.